Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review

Oliver Warren; Kaushik Mandal; Vassilis Hadjianastassiou; Lisa Knowlton; Sukhmeet Panesar; Kokotsakis John; Ara Darzi; Thanos Athanasiou

doi:10.1016/j.athoracsur.2006.10.033

Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review

Oliver Warren, Kaushik Mandal, Vassilis Hadjianastassiou, Lisa Knowlton, Sukhmeet Panesar, Kokotsakis John, Ara Darzi, Thanos Athanasiou

Department of Surgery

Research output: Contribution to journal › Review article › peer-review

114 Scopus citations

Abstract

Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.

Original language	English (US)
Pages (from-to)	707-714
Number of pages	8
Journal	Annals of Thoracic Surgery
Volume	83
Issue number	2
DOIs	https://doi.org/10.1016/j.athoracsur.2006.10.033
State	Published - Feb 2007

All Science Journal Classification (ASJC) codes

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.athoracsur.2006.10.033

Cite this

@article{6e9592124e4f4bc683084f7f2f00bd26,

title = "Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review",

abstract = "Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.",

author = "Oliver Warren and Kaushik Mandal and Vassilis Hadjianastassiou and Lisa Knowlton and Sukhmeet Panesar and Kokotsakis John and Ara Darzi and Thanos Athanasiou",

year = "2007",

month = feb,

doi = "10.1016/j.athoracsur.2006.10.033",

language = "English (US)",

volume = "83",

pages = "707--714",

journal = "Annals of Thoracic Surgery",

issn = "0003-4975",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Recombinant Activated Factor VII in Cardiac Surgery

T2 - A Systematic Review

AU - Warren, Oliver

AU - Mandal, Kaushik

AU - Hadjianastassiou, Vassilis

AU - Knowlton, Lisa

AU - Panesar, Sukhmeet

AU - John, Kokotsakis

AU - Darzi, Ara

AU - Athanasiou, Thanos

PY - 2007/2

Y1 - 2007/2

N2 - Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.

AB - Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.

UR - http://www.scopus.com/inward/record.url?scp=33846443612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846443612&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2006.10.033

DO - 10.1016/j.athoracsur.2006.10.033

M3 - Review article

C2 - 17258029

AN - SCOPUS:33846443612

SN - 0003-4975

VL - 83

SP - 707

EP - 714

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

IS - 2

ER -

Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this